Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAG 17

Drug Profile

RAG 17

Alternative Names: RAG-17

Latest Information Update: 22 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ractigen Therapeutics
  • Class Drug conjugates; Oligonucleotides; Small interfering RNA
  • Mechanism of Action RNA interference; Superoxide dismutase 1 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase 0 Amyotrophic lateral sclerosis

Most Recent Events

  • 15 May 2024 The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approves the investigational new drug (IND) application for phase I clinical trial in Amyotrophic lateral sclerosis (ALS)
  • 22 May 2023 Phase-0 for Amyotrophic lateral sclerosis in China (Intrathecal) (NCT05903690)
  • 08 Mar 2023 RAG 17 is available for licensing as of 08 Mar 2023. https://www.ractigen.com/industrial-partnerships/ (Ractigen Therapeutics website, February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top